Ivabradine in Management of Heart Failure: a Critical Appraisal

Gabriela Orasanu; Sadeer G. Al-Kindi; Guilherme H. Oliveira

doi:10.1007/s11897-016-0276-x

Ivabradine in Management of Heart Failure: a Critical Appraisal

Gabriela Orasanu, Sadeer G. Al-Kindi, Guilherme H. Oliveira

Research output: Contribution to journal › Review article › peer-review

Abstract

Elevated resting heart rate has been linked to poor outcomes in patients with chronic systolic heart failure. Blockade of funny current channel with ivabradine reduces heart rate without inotropic effects. Ivabradine was recently approved by US Food and Drug Administration for patients with stable, symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤35 %, who are in sinus rhythm with resting heart rate (HR) ≥ 70 bpm and either are on maximally tolerated doses of beta-blockers, or have a contraindication to beta-blockers. This article will review and evaluate the data supporting the use of ivabradine in patients with HF and explore its mechanisms and physiologic effects.

Original language	English (US)
Pages (from-to)	60-69
Number of pages	10
Journal	Current heart failure reports
Volume	13
Issue number	1
DOIs	https://doi.org/10.1007/s11897-016-0276-x
State	Published - Feb 1 2016

Keywords

Funny channel
Heart failure
Heart rate
Hospitalization
Inhibitor
Ivabradine

ASJC Scopus subject areas

Emergency Medicine
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s11897-016-0276-x

Cite this

@article{792e44deb5024e0d9948748b8d6f3ba9,

title = "Ivabradine in Management of Heart Failure: a Critical Appraisal",

abstract = "Elevated resting heart rate has been linked to poor outcomes in patients with chronic systolic heart failure. Blockade of funny current channel with ivabradine reduces heart rate without inotropic effects. Ivabradine was recently approved by US Food and Drug Administration for patients with stable, symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤35 %, who are in sinus rhythm with resting heart rate (HR) ≥ 70 bpm and either are on maximally tolerated doses of beta-blockers, or have a contraindication to beta-blockers. This article will review and evaluate the data supporting the use of ivabradine in patients with HF and explore its mechanisms and physiologic effects.",

keywords = "Funny channel, Heart failure, Heart rate, Hospitalization, Inhibitor, Ivabradine",

author = "Gabriela Orasanu and Al-Kindi, {Sadeer G.} and Oliveira, {Guilherme H.}",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = feb,

day = "1",

doi = "10.1007/s11897-016-0276-x",

language = "English (US)",

volume = "13",

pages = "60--69",

journal = "Current heart failure reports",

issn = "1546-9530",

publisher = "Current Science, Inc.",

number = "1",

}

TY - JOUR

T1 - Ivabradine in Management of Heart Failure

T2 - a Critical Appraisal

AU - Orasanu, Gabriela

AU - Al-Kindi, Sadeer G.

AU - Oliveira, Guilherme H.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Elevated resting heart rate has been linked to poor outcomes in patients with chronic systolic heart failure. Blockade of funny current channel with ivabradine reduces heart rate without inotropic effects. Ivabradine was recently approved by US Food and Drug Administration for patients with stable, symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤35 %, who are in sinus rhythm with resting heart rate (HR) ≥ 70 bpm and either are on maximally tolerated doses of beta-blockers, or have a contraindication to beta-blockers. This article will review and evaluate the data supporting the use of ivabradine in patients with HF and explore its mechanisms and physiologic effects.

AB - Elevated resting heart rate has been linked to poor outcomes in patients with chronic systolic heart failure. Blockade of funny current channel with ivabradine reduces heart rate without inotropic effects. Ivabradine was recently approved by US Food and Drug Administration for patients with stable, symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤35 %, who are in sinus rhythm with resting heart rate (HR) ≥ 70 bpm and either are on maximally tolerated doses of beta-blockers, or have a contraindication to beta-blockers. This article will review and evaluate the data supporting the use of ivabradine in patients with HF and explore its mechanisms and physiologic effects.

KW - Funny channel

KW - Heart failure

KW - Heart rate

KW - Hospitalization

KW - Inhibitor

KW - Ivabradine

UR - http://www.scopus.com/inward/record.url?scp=84958043277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958043277&partnerID=8YFLogxK

U2 - 10.1007/s11897-016-0276-x

DO - 10.1007/s11897-016-0276-x

M3 - Review article

C2 - 26797824

AN - SCOPUS:84958043277

SN - 1546-9530

VL - 13

SP - 60

EP - 69

JO - Current heart failure reports

JF - Current heart failure reports

IS - 1

ER -

Ivabradine in Management of Heart Failure: a Critical Appraisal

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this